ACADIA Pharmaceuticals (MEX:ACAD) Tariff Resilience Score: 7/10 (As of Jul. 01, 2026)


MEX:ACAD ACADIA Pharmaceuticals Inc MEX:ACAD
73 GF Score
Price MXN362.00
GF Value MXN357.85
Valuation Fairly Valued
! 9 Warning Signs
View Full Analysis

What is ACADIA Pharmaceuticals Tariff Resilience Score?

ACADIA Pharmaceuticals MEX:ACAD 73 Tariff Resilience Score is 7 as of Jul. 01, 2026. GuruFocus rates MEX:ACAD with a GF Score™ of 73/100 and a GF Value™ of MXN357.85 (Fairly Valued). The stock has 9 warning signs investors should review. Among 1,374 Biotechnology companies, ACADIA Pharmaceuticals ranks better than 90.39% on this metric.

ACADIA Pharmaceuticals has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

ACADIA Pharmaceuticals has Pharmaceutical company with limited exposure to tariffs. Primarily domestic operations with some international supply chain dependencies. Historical data shows minimal impact from tariffs, with strong pricing power.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes ACADIA Pharmaceuticals might have Highly Resilient.

ACADIA Pharmaceuticals  (MEX:ACAD) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

ACADIA Pharmaceuticals Tariff Resilience Score Related Terms

MEX:ACAD vs VKTX, EWTX, DNLI: Tariff Resilience Score Comparison

For the Biotechnology subindustry, ACADIA Pharmaceuticals's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ACADIA Pharmaceuticals Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where ACADIA Pharmaceuticals's Tariff Resilience Score falls into.


MEX:ACAD
73GF Score
ACADIA Pharmaceuticals Inc MEX:ACAD
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
ACADIA Pharmaceuticals (MEX:ACAD) has a Tariff Resilience Score of 7 as of Jul. 01, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, ACADIA Pharmaceuticals ranks #132 out of 1374 companies in the Biotechnology industry, placing it in the top 9.6%.
Is ACADIA Pharmaceuticals' Tariff Resilience Score too high?
ACADIA Pharmaceuticals' current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. ACADIA Pharmaceuticals' value of 7 is 75% above this industry median. Based on the distribution chart, ACADIA Pharmaceuticals ranks #132 out of 1374 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, ACADIA Pharmaceuticals has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ACADIA Pharmaceuticals' Tariff Resilience Score compare to VKTX and EWTX?
According to the Biotechnology industry distribution chart, ACADIA Pharmaceuticals ranks #132 out of 1374 companies for Tariff Resilience Score. This places ACADIA Pharmaceuticals in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. ACADIA Pharmaceuticals' value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,374 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ACADIA Pharmaceuticals's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ACADIA Pharmaceuticals's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACADIA Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals (MEX:ACAD) is currently considered Fairly Valued. The stock's GF Value™ is MXN357.85, compared to a current price of MXN362.00 — trading 1.2% above its estimated fair value. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. ACADIA Pharmaceuticals' overall GF Score™ is 73/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For ACADIA Pharmaceuticals (MEX:ACAD), the current Tariff Resilience Score is 7 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ACADIA Pharmaceuticals (MEX:ACAD) Overvalued in 2026?

Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be overvalued. The current stock price of MXN362.00 is trading 1.2% above its estimated GF Value™ of MXN357.85. GuruFocus considers ACADIA Pharmaceuticals to be Fairly Valued.

Key valuation signals for MEX:ACAD:

  • Tariff Resilience Score: 7
  • GF Value™: MXN357.85 vs. price of MXN362.00 (1.2% above fair value)
  • GF Score™: 73/100 with 9 warning signs
  • Industry Position: 75% above the Biotechnology median (#132 of 1374)

No single metric tells the full story. See the MEX:ACAD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ACADIA Pharmaceuticals Business Description

Other Exchanges ACAD:USADR6:Germany
Address 12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
73GF Score

Get the complete analysis for MEX:ACAD

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN362.00
Price
MXN357.85
GF Value